Chengdu Easton Biopharmaceuticals , Ltd. EBIT

The latest EBIT for 688513.SS is $240M as of June 2026. That compares with $250M in the prior-year period — down 2.0% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Chengdu Easton Biopharmaceuticals , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 688513.SS's EBIT moved from $250M to $240M — a 2.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chengdu Easton Biopharmaceuticals , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 688513.SS currently prints $240M for EBIT, while the sector average sits near $130B. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at Chengdu Easton Biopharmaceuticals , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $240M for 688513.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting 688513.SS's EBIT ($240M), review year-over-year change from $250M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.